Unlocking Neogen's Potential J.P. Morgan Healthcare Conference January 14, 2026 © 2026 Neogen Corporation. All rights reserved. | 1 Disclaimer Forward-Looking Statements This presentation includes "forward-looking statements" as that term is defined in Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Neogen's current expectations and are subject to risks and uncertainties, which could cause a ...

Financial Data and Key Metrics Changes - Total Q2 revenues were $224.7 million, increasing 2.9% on a core basis, with foreign currency contributing 0.9% and divestitures and discontinued products being a headwind of 6.6% [12][19] - Adjusted EBITDA was $48.7 million, representing a margin of 21.7%, an improvement of 470 basis points from Q1 [19] - Gross margin in Q2 was 47.5%, a sequential improvement of 210 basis points from Q1, primarily due to volume and lower tariff costs [18] Business Line Data and Key Metrics Changes - Food safety segment revenues were $165.6 million, with core revenue growth of 4.1%, driven by strong growth in indicator testing and culture media product categories [13] - Animal safety segment revenues were $59.1 million, with core revenue growth approximately flat compared to the prior year, although biosecurity products saw solid growth [15] - The global genomics business had core revenue growth accelerate to 6%, with solid growth in the bovine market [16] Market Data and Key Metrics Changes - Core revenue growth in Q2 was led by the LATAM region, up high single digits, while the U.S. and Canada region had mid-single-digit growth [17] - The APAC region saw low single-digit core growth, while the EMEA region experienced a low single-digit decline [17] Company Strategy and Development Direction - The company is focused on stabilizing and strengthening its core business, with a clear emphasis on improved top-line growth and profitability [4] - A rigorous process-oriented approach to commercial excellence is being implemented, emphasizing strong operational planning and data-driven decisions [5] - The leadership team has been strengthened with experienced operators to drive transformation and operational efficiency [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in overcoming recent macroeconomic and execution-related headwinds, with a belief that challenges are solvable or transitory [4][10] - The company raised its full-year guidance for fiscal 2026, expecting revenue in the range of $845 million to $855 million and adjusted EBITDA of approximately $175 million [20] Other Important Information - The company is in the process of divesting its global genomics business, which is expected to simplify operations and enhance margins [22][23] - The integration of Petrifilm is on track for the Q2 of fiscal 2027, with positive progress in production testing and product validation [9][56] Q&A Session Summary Question: Can you discuss the new management team and how long it will take for them to gel? - Management highlighted the recruitment of top-tier talent and emphasized the importance of experienced leaders in diagnostics and life sciences to drive operational excellence [30][32] Question: What was the headwind to margins from sample handling? - Management acknowledged challenges in sample collection but indicated improvements are expected in the second half of the year, with a focus on profitability [34][36] Question: Why hasn't the implied H2 growth or margin been higher? - Management stated that a conservative approach is being taken due to lingering macroeconomic weaknesses and the need for the new team to settle in [41][42] Question: Were there any one-time revenue tailwinds in the quarter? - Management noted a $2 million insecticide tailwind in Q2 but indicated that it was the only significant one-time factor [45] Question: What changes in the commercial organization have contributed to the strong quarter? - Management emphasized a focus on the basics, driving simplicity, and implementing a weekly forecasting process to enhance predictability [52][54] Question: How is the Petrifilm manufacturing process progressing? - Management expressed confidence in the Petrifilm project, stating that production testing is going well and the timeline remains on track [56]

Financial Data and Key Metrics Changes - Total second quarter revenues were $224.7 million, increasing 2.9% on a core basis, with foreign currency contributing 0.9% and divestitures and discontinued products impacting by 6.6% [12][19] - Adjusted EBITDA was $48.7 million, representing a margin of 21.7%, an improvement of 470 basis points from the first quarter [19] - Gross margin in the second quarter was 47.5%, a sequential improvement of 210 basis points from the first quarter, primarily due to volume and lower tariff costs [18] Business Line Data and Key Metrics Changes - Food safety segment revenues were $165.6 million, with core revenue growth of 4.1%, driven by strong growth in indicator testing and culture media product categories [13] - Animal safety segment revenues were $59.1 million, with core revenue growth approximately flat compared to the prior year quarter, despite solid growth in biosecurity products [15] - Global genomics business had core revenue growth accelerate to 6%, with solid growth in the bovine market [16] Market Data and Key Metrics Changes - Core revenue growth in the Latham region was high single digits, while the U.S. and Canada region had mid-single-digit growth [17] - APAC region saw low single-digit core growth, led by pathogen detection products, while EMEA region had a low single-digit core growth decline [17] Company Strategy and Development Direction - The company is focused on improving top-line growth and profitability, with a transformation strategy centered on stabilizing and strengthening its core [4] - A rigorous process-oriented approach to commercial excellence is being implemented, emphasizing strong operational planning and data-driven decisions [5] - The leadership team has been strengthened with experienced operators to drive growth and innovation [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in overcoming macroeconomic and execution-related headwinds, with a belief that challenges are solvable or transitory [4] - The company raised its full-year guidance for fiscal 2026, expecting revenue in the range of $845 million-$855 million and adjusted EBITDA of approximately $175 million [20] - Management acknowledged the importance of building credibility with investors and maintaining a conservative approach to guidance amid lingering market weaknesses [42] Other Important Information - The company is in the process of divesting its global genomics business, which is expected to simplify operations and enhance incremental margins [22][23] - The integration of Petrifilm is on track for the second quarter of fiscal 2027, with positive progress in production testing and product validation [9][56] Q&A Session Summary Question: Can you discuss the new management team and their integration? - Management highlighted the recruitment of top-tier talent with experience in diagnostics and life sciences, emphasizing the importance of operational excellence and alignment on priorities [30][32] Question: What are the headwinds to margins from sample handling? - Management acknowledged challenges in sample collection but expressed optimism for profitability improvements in the second half of the year [34][36] Question: Why is the implied H2 growth or margin not higher? - Management indicated a prudent approach to guidance, focusing on sustainable performance and the settling in of the new team [41][42] Question: Were there any one-time revenue tailwinds in the quarter? - Management noted a $2 million insecticide tailwind in the animal safety segment as the only significant one-time factor [45] Question: What changes in the commercial organization have contributed to recent success? - Management emphasized a focus on basics, driving simplicity, and implementing a weekly forecasting process to enhance predictability [51][52]

Financial Performance - Q4 FY25 revenue was $225.5 million, a decrease from $236.8 million in Q4 FY24[11] - Adjusted EBITDA for Q4 FY25 was $40.6 million, compared to $53.0 million in Q4 FY24, with a margin of 18.0% versus 22.4%[12] - Adjusted net income decreased to $11.3 million ($0.05 per share) in Q4 FY25 from $22.4 million ($0.10 per share) in Q4 FY24[13] - Core revenue growth in the Food Safety segment was (1.3)%, while the Animal Safety segment experienced a core revenue growth of (6.7)%[15] Balance Sheet and Capital Allocation - As of May 31, 2025, gross debt was $900 million and net debt was $771 million[17] - Pro forma net debt, after accounting for cash and equivalents, is $656 million with gross debt at $800 million[17] - Net proceeds from the Cleaners & Disinfectants divestiture were approximately $115 million, with $100 million allocated for debt paydown in Q1[19] FY26 Outlook - The company anticipates FY26 revenue to be between $820 million and $840 million[21] - Adjusted EBITDA is projected to be in the range of $165 million to $175 million[21] - Capital expenditures are estimated to be around $50 million, including approximately $35 million for integration-related expenses[21]